CONVINCE: COlchicine for preventioN of Vascular Inflammation in Non-CardioEmbolic stroke
CONVINCE is a randomised clinical trial of low dose colchicine for secondary prevention after stroke.
Accumulating evidence indicates that inflammation is of key importance to the destabilisation of atherosclerotic plaques. Colchicine shows anti-inflammatory effects mediated through a reduction in macrophage/monocyte activity leading to reduction in inflammatory changes which may destabilise arterial plaques and result in thromboembolism from the plaques.
The CONVINCE study is randomising participants post non-cardioembolic stoke or high-risk TIA to receive usual care or usual care plus 500 micrograms of colchicine per day. The study aims to find if adding daily low-dose colchicine to usual care shows a reduction in recurrence of non-fatal ischaemic stroke, TIA, myocardial infarction, hospitalisation for unstable angina, cardiac arrest and vascular death after ischaemic stroke between the two arms of the study.
Expertise and Subject area
- Research Theme: Stroke
- Metatheme: Health and Wellbeing
- Faculty: Health and Wellbeing: Lancashire Clinical Trials Unit
- Chief Investigator Global: Professor Peter Kelley, University College Dublin Clinical Research Centre, Mater Misericordiae University Hospital, Dublin.
- Chief Investigator UK: Dr Chris Price, Clinical Reader, Institute of Neuroscience, Newcastle University UK.
- Lancashire Clinical Trials Unit Contact: Mrs Denise Forshaw, Principal Trial Manager, email@example.com, 01772 893629.
Dr John Heney - Associate Clinical Trial Manager, Miss Alexandra Haig - Senior Trials Assistant, Miss Alison Gibbon - Trials Assistant, Miss Carole Bruce - Data Coordinator.
Clients or Funders
Health Research Board of Ireland
2016 - 2021